Terflavoxate hydrochloride | 86433-39-8

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 黄酮类化合物
• 英文名称: Terflavoxate hydrochloride
• 英文别名: 1,1-dimethyl-2-(1-piperidinyl)ethyl 2-phenyl-3-methyl-4-oxo-4H-1-benzopyran-8-carboxylate hydrochloride；terflavoxate hydrochloride；hydron;(2-methyl-1-piperidin-1-ylpropan-2-yl) 3-methyl-4-oxo-2-phenylchromene-8-carboxylate;chloride
• CAS: 86433-39-8
• 化学式: C₂₆H₂₉NO₄*ClH
• 分子量: 455.982
• InChiKey: MKYPNZBEBRPWDQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.61
• 重原子数：
  32
• 可旋转键数：
  6
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为产物：
  描述：

  alpha,alpha-二甲基哌啶-1-乙醇 、 2-phenyl-3-methyl-4-oxo-4H-1-benzopyran-8-carbonyl chloride 生成 Terflavoxate hydrochloride
  参考文献：
  名称：

  GB2104507A

  摘要：

  公开号：

文献信息

• Heterobicyclic compounds as antagogists of alpha-1 adrenergic and SHT1A receptors
  申请人：RECORDATI S.A. CHEMICAL and PHARMACEUTICAL COMPANY

  公开号：EP0558245A1

  公开（公告）日：1993-09-01

  There are disclosed compounds of the general formula The heteroatom X is preferably oxygen, but may have other values. The group W is preferably a carbonyl group, but may have other values. The preferred heterocyclic ring is thus a 4-oxo-4H-1-benzopyran ring. This may have a wide range of R₂, R₃, R₆ and R₇ substituents. Y is a linking group, chosen from a wide range, but including -COO- , -CONH- , -O- , -SO₂- and -SO₂NH-. Z is an alkylene chain, and B is a complex amine. These compounds and their prodrugs, enantiomers, diastereoisomers, N-oxides and pharmaceutically acceptable salts are useful for the treatment of hypertension and urinary tract troubles associated with benign prostatic hypertrophy, and for the treatment of other diseases.

  已公开的化合物通式如下 杂原子 X 最好是氧，但也可以有其他值。基团 W 最好是羰基，但也可以有其他值。因此，优选的杂环是 4-氧代-4H-1-苯并吡喃环。它可以有多种 R₂、R₃、R₆ 和 R₇ 取代基。Y 是连接基团，可选范围很广，但包括-COO-、-CONH-、-O-、-SO₂- 和-SO₂NH-。Z 是亚烷基链，B 是复合胺。这些化合物及其原药、对映体、非对映异构体、N-氧化物和药学上可接受的盐类可用于治疗与良性前列腺肥大相关的高血压和尿路问题，也可用于治疗其他疾病。
• REMEDIES FOR URINARY FREQUENCY
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1447096A1

  公开（公告）日：2004-08-18

  The present invention relates to an agent for the treatment and/or prevention of pollakiuria comprising a compound having an antagonism to an EP1 receptor which is a prostaglandin E2 receptor subtype. A compound having an antagonism to an EP1 receptor antagonistically acts on an EP1 receptor which is a prostaglandin PGE2 receptor subtype and significantly shows a suppressive activity for urination frequency in models where pollakiuria is induced. Therefore, it is effective for the treatment and/or prevention of pollakiuria (that which is due to nurogenic bladder, nervous bladder, stimulated bladder, unstable bladder, benign prostatic hypertrophy, etc.).

  本发明涉及一种用于治疗和/或预防花粉尿症的制剂，该制剂包含一种对前列腺素E2受体亚型的EP1受体具有拮抗作用的化合物。具有 EP1 受体拮抗作用的化合物可拮抗属于前列腺素 PGE2 受体亚型的 EP1 受体，并在诱导花粉尿症的模型中显著显示出抑制排尿次数的活性。因此，它对治疗和/或预防花粉尿症（由神经性膀胱、神经性膀胱、刺激性膀胱、不稳定膀胱、良性前列腺肥大等引起的花粉尿症）有效。
• Remedies for urinary frequency
  申请人：Maruyama Takayuki

  公开号：US20060100195A1

  公开（公告）日：2006-05-11

  The present invention relates to an agent for the treatment and/or prevention of pollakiuria comprising a compound having an antagonism to an EP 1 receptor which is a prostaglandin E 2 receptor subtype. A compound having an antagonism to an EP 1 receptor antagonistically acts on an EP 1 receptor which is a prostaglandin PGE 2 receptor subtype and significantly shows a suppressive activity for urination frequency in models where pollakiuria is induced. Therefore, it is effective for the treatment and/or prevention of pollakiuria (that which is due to nurogenic bladder, nervous bladder, stimulated bladder, unstable bladder, benign prostatic hypertrophy, etc.).

  本发明涉及一种用于治疗和/或预防花粉尿症的制剂，该制剂包含一种具有拮抗 EP 1 受体（前列腺素 E 2 受体亚型的拮抗剂。具有拮抗 EP 1 受体具有拮抗作用的化合物可拮抗 EP 1 受体上起拮抗作用，该受体是前列腺素 PGE 2 受体亚型的 EP 1 受体上，并在诱导花粉尿的模型中明显显示出抑制排尿次数的活性。因此，它对治疗和/或预防花粉尿（由神经性膀胱、神经性膀胱、刺激性膀胱、不稳定膀胱、良性前列腺肥大等引起的花粉尿）有效。
• US5474994A
  申请人：——

  公开号：US5474994A

  公开（公告）日：1995-12-12
• US5605896A
  申请人：——

  公开号：US5605896A

  公开（公告）日：1997-02-25